Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study

References

• Tzioufas AG, Katsikis PD, Youinou PY, Moutsopoulos HM. Sjögren’s syndrome: an oligo-monoclonal B cell process. Clin Exp Rheumatol 1990;8(Suppl 5):17–21.
   PubMedGoogle Scholar
• Tzioufas AG, Youinou P, Moutsopoulos HM. Sjögren’s syndrome. In: Isenberg DA, Maddison P, Woo P, Glass D, Breedveld F, editors. Oxford textbook of rheumatology, 3rd edn. Oxford: Oxford University Press, 2004:921–33.
   Google Scholar
• Sugai S, Shimizu S, Tachibana J, Sawada M, Yoshioka R, Hirose Y, et al. Hypergammaglobulinemic purpura in patients with Sjögren’s syndrome: a report of nine cases and a review of the Japanese literature. Jpn J Med 1989;28:148–55.
   PubMedGoogle Scholar
• Alexander E, Provost TT. Sjögren’s syndrome. Association of cutaneous vasculitis with central nervous system disease. Arch Dermatol 1987;123:801–10.
   PubMedGoogle Scholar
• Ramos-Casals M, Anaya JM, García-Carrasco M, Rosas J, Bové A, Claver G, et al. Cutaneous vasculitis in primary Sjögren’s syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) 2004;83:96–106.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Isola M, Corazza L, Maset M, Monti G, Gabrielli A, et al. Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol 2012;30:S48–52.
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjögren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren’s Syndrome. Arthritis Rheum 1999;42:1765–72.
   PubMed Web of Science ®Google Scholar
• Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009;88:284–93.
   PubMed Web of Science ®Google Scholar
• Sutcliffe N, Inanc M, Speight P, Isenberg D. Predictors of lymphoma development in primary Sjögren’s syndrome. Semin Arthritis Rheum 1998;28:80–7.
   PubMed Web of Science ®Google Scholar
• Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum 1996;39:767–72.
   PubMed Web of Science ®Google Scholar
• Anaya JM, McGuff HS, Banks PM, Talal N. Clinicopathological factors relating malignant lymphoma with Sjögren’s syndrome. Semin Arthritis Rheum 1996;25:337–46.
   PubMed Web of Science ®Google Scholar
• Block KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjögren’s syndrome. A clinical, pathological and serological study of sixty-two cases. Medicine (Baltimore) 1965;44:187–231.
   PubMed Web of Science ®Google Scholar
• Goltz RW, Good RA. Benign hyperglobulinemic purpura: relation to Mikulicz disease, sicca syndrome and epidermolysis bullosa dystrophia. Arch Dermatol 1961;83:26–39.
   PubMedGoogle Scholar
• Alexander EL, Provost TT. Cutaneous manifestations of primary Sjögren’s syndrome: a reflection of vasculitis and association with anti-Ro (SS-A) antibodies. J Invest Dermatol 1983;80:386–91.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gleich GJ, Bayrid ED, Vaughan JH. Benign hypergammaglobulinemic purpura of Waldenström. Medicine (Baltimore) 1971;50:113–23.
   PubMed Web of Science ®Google Scholar
• Alexander EL. Inflammatory vascular disease in Sjögren’s syndrome. In: Talal N, Moutsopoulos HM, Kassan SS, editors. Sjögren’s syndrome, clinical and immunological aspects. Berlin: Springer-Verlag, 1987:102.
   Google Scholar
• Baldini C, Pepe P, Luciano N, Ferro F, Talarico R, Grossi S, et al. A clinical prediction rule for lymphoma development in primary Sjögren’s syndrome. J Rheumatol 2012;39:804–8.
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Hatron PY, et al. Preliminary criteria for the classification of Sjögren’s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340–7.
   PubMed Web of Science ®Google Scholar
• De Vita S, Boiocchi M, Sorrentino D, Carbone A, Avellini C, Dolcetti R, et al. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren’s syndrome. Arthritis Rheum 1997;40:318–31.
   PubMed Web of Science ®Google Scholar
• De Vita S, De Marchi G, Sacco S, Gremese E, Fabris M, Ferraccioli G. Preliminary classification of nonmalignant B cell proliferation in Sjögren’s syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach. Blood Cells Mol Dis 2001;27:757–66.
   PubMed Web of Science ®Google Scholar
• Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775–88.
   Google Scholar
• Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8.
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren’s syndrome. Nat Rev Rheumatol 2010;6:529–37.
   PubMed Web of Science ®Google Scholar
• Gasparotto D, De Vita S, De Re V, Marzotto A, De Marchi G, Scott CA, et al. Extrasalivary lymphoma development in Sjögren’s syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum 2003;48:3181–6.
   PubMedGoogle Scholar
• Quartuccio L, Isola M, Baldini C, Priori R, Bartoloni Bocci E, Carubbi F, et al. Biomarkers of lymphoma in Sjögren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 2014;51:75–80.
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Salvin S, Corazza L, Zabotti A, Fabris M. Cryoglobulinaemia related to Sjögren’s syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. Rheumatology (Oxford) 2012;51:627–33.
   Google Scholar
• Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, Isola M, et al. BLyS upregulation in Sjögren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013;52:276–81.
   PubMed Web of Science ®Google Scholar
• Alexander EL, Provost TT, Stevens MB, Alexander GE. Neurologic complications of primary Sjögren’s syndrome. Medicine (Baltimore) 1982;61:247–57.
   PubMed Web of Science ®Google Scholar
• Harley JB, Alexander EL, Bias WB, Fox OF, Provost TT, Reichlin M, et al. Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjögren’s syndrome. Arthritis Rheum 1986;29:196–206.
   PubMed Web of Science ®Google Scholar